The Effect of Sulpiride on Negative Symptoms of Schizophrenia

Michel Petit; Michèle Zann; Philippe Lesieur; Lucien Colonna

doi:10.1192/bjp.150.2.270a

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

References

Delay, J., Deniker, P., Green, A. & Mordret, M. Y. (1957) Le syndrome excitomoteur provoqué par les médicaments neuroleptiques. Presse Médicale, 65, 1771–1774.Google Scholar

Collard, J. (1969) Le sulpiride, un neuroleptique singulier, anti- autistique et thymoanaleptique. Sem. Hôpitaux Paris, 45, 3028–3031.Google Scholar

Sokoloff, P., Martres, M. P. & Schwartz, J. C. (1980) Three classes of dopamine receptors (D-2, D-3, D-4) identified by binding studies with ³H-apomorphine and ³H-domperidone. Naumyn-Schmiedeberg's Archives of Pharmacology, 315, 89–102.CrossRef Google Scholar PubMed

Brown, R. J. & Arbuthnott, G. W. (1983) The electrophysiology of dopamine (Dé) receptors: a study of the actions of dopamine on corticostriatal transmission. Neuroscience, 10, 349–355.Google Scholar

Johnstone, E. C., Crow, F. J., Frith, C. D., Carney, N. W. P. & Price, J. S. (1978) Mechanism of the anti-psychotic effect in the treatment of acute schizophrenia. Lancet, 22, 848–851.Google Scholar

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

New, James S. and Takaki, Katherine S. 1988. Vol. 23, Issue. , p. 1.

CrossRef

Lepola, U. Koskinen, T. Rimón, R. Salo, H. and Gordin, A. 1989. Sulpiride and perphenazine in schizophrenia. Acta Psychiatrica Scandinavica, Vol. 80, Issue. 1, p. 92.

Martinot, JL Paillère-Martinot, ML Loc'h, C Péron Magnan, P Mazoyer, B Lecrubier, Y Hardy, P Beaufils, B Allilaire, JF Mazière, B Slama, MF and Syrota, A 1990. Central D2receptor blockade and antipsychotic effects of neuroleptics. Preliminary study with positron emission tomography. Psychiatry and Psychobiology, Vol. 5, Issue. 4, p. 231.

Silverstone, Trevor 1990. Clinically relevant differences between antipsychotic compounds. Acta Psychiatrica Scandinavica, Vol. 82, Issue. S358, p. 88.

King, D.J. Devaney, N. Cooper, S.J. Blomqvist, M. and Mitchell, M.J. 1990. Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. Journal of Psychopharmacology, Vol. 4, Issue. 2, p. 83.

Soni, S. D. Mallik, A. and Schiff, A. A. 1990. Sulpiride in negative schizophrenia: A placebo‐controlled double‐blind assessment. Human Psychopharmacology: Clinical and Experimental, Vol. 5, Issue. 3, p. 233.

de Beaurepaire, R. 1991. Brain Dopaminergic Systems: Imaging with Positron Tomography. p. 147.

Dollfus, Sonia Petit, Michel Menard, Jean F. and Lesieur, Philippe 1992. Amisulpride versus bromocriptine in infantile autism: A controlled crossover comparative study of two drugs with opposite effects on dopaminergic function. Journal of Autism and Developmental Disorders, Vol. 22, Issue. 1, p. 47.

Fleischhacker, W.W. and Whitworth, A.B. 1993. Classical antipsychotics in the treatment of negative symptoms. European Neuropsychopharmacology, Vol. 3, Issue. 3, p. 210.

Tegeler, J. 1993. Therapieresistenz unter Neuroleptikabehandlung. p. 115.

Michels, Robert and Marzuk, Peter M. 1993. Progress in Psychiatry. New England Journal of Medicine, Vol. 329, Issue. 8, p. 552.

Meltzer, Herbert Y. Lee, Myung A. and Ranjan, Rakesh 1994. Recent advances in the pharmacotherapy of schxzophrenia. Acta Psychiatrica Scandinavica, Vol. 90, Issue. s384, p. 95.

Laux, G. 1994. Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. p. 207.

Dollfus, S. and Petit, M. 1995. Análisis de componentes principales de la PANSS y la SANS-SAPS en esquizofrenia: su estabilidad en una fase aguda. European psychiatry (Ed. Española), Vol. 2, Issue. 4, p. 219.

Mucci, A. Nolfe, G. and Maj, M. 1995. Levosulpiride: a review of its clinical use in psychiatry. Pharmacological Research, Vol. 31, Issue. 2, p. 95.

Caley, Charles F. and Weber, Stanley S. 1995. Sulpiride: an Antipsychotic with Selective Dopaminergic Antagonist Properties. Annals of Pharmacotherapy, Vol. 29, Issue. 2, p. 152.

Dollfus, S and Petit, M 1995. Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase. European Psychiatry, Vol. 10, Issue. 2, p. 97.

Storey, V.J. Middlemiss, D.N. and Reavill, C. 1995. Effect of haloperidol and (−)-sulpiride on dopamine agonist-induced hypoactivity. Neuropharmacology, Vol. 34, Issue. 4, p. 449.

Pantelis, Christos and Barnes, Thomas R.E. 1996. Drug Strategies and Treatment-Resistant Schizophrenia. Australian & New Zealand Journal of Psychiatry, Vol. 30, Issue. 1, p. 20.

Ronchi, Diana De Ruggeri, Mirella Belelli, Gabriella and Volterra, Vittorio 1996. Levosulpiride versus pimozide in negative symptoms of schizophrenia. Current Therapeutic Research, Vol. 57, Issue. 10, p. 797.

Download full list

Article contents

The Effect of Sulpiride on Negative Symptoms of Schizophrenia

Abstract

References

eLetters

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

The Effect of Sulpiride on Negative Symptoms of Schizophrenia

Abstract

References

eLetters

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests